Market Spotlight: Psoriatic Arthritis
Market Spotlight: Psoriatic Arthritis
$1,318.00
This Market Spotlight report covers the psoriatic arthritis market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the psoriatic arthritis market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- The approved drugs in the psoriatic arthritis space focus on a wide variety of targets. The majority of approved drugs are administered via the subcutaneous route, with the remainder being intravenous, intramuscular, oral, and topical formulations.
- The majority of industry-sponsored drugs in active clinical development for psoriatic arthritis are in Phase III, with only one drug in the NDA/BLA stage.
- Therapies in development for psoriatic arthritis focus on targets such as TNF-alpha, IL-23, JAK/STAT, IL-17, selectins, and tyrosine kinase 2. These drugs are administered via the oral, subcutaneous, and intravenous routes.
- High-impact upcoming events for drugs in the psoriatic arthritis space comprise topline Phase III trial results for bimekizumab, topline Phase II trial results for BMS-986165, and an estimated PDUFA date as well as expected CHMP supplemental filing results for Tremfya.
- The overall likelihood of approval of a Phase I psoriasis asset is 13%, and the average probability a drug advances from Phase III is 75%. Drugs, on average, take 7.7 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for psoriatic arthritis have been in the late phases of development, with 79% of trials in Phase III–IV, and only 21% in Phase I–II.
- The US leads in terms of the number of psoriatic arthritis clinical trials globally, while Germany leads the major European markets.
- Clinical trial activity in the psoriatic arthritis space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for psoriatic arthritis, with 31 trials.
- AbbVie leads industry sponsors with the highest overall number of clinical trials for psoriatic arthritis, followed by Bristol Myers Squibb.
CONTENTS
7 OVERVIEW
8 KEY TAKEAWAYS
9 DISEASE BACKGROUND
9 Disease definition
9 Patient subtypes
9 Symptoms
10 Risk factors
10 Diagnosis
11 TREATMENT
11 Topical treatments
11 NSAIDs
11 Corticosteroids
11 Light therapy
11 DMARDs
12 Biologics
13 EPIDEMIOLOGY
13 Prevalence
13 Prevalence among patients with psoriasis
15 MARKETED DRUGS
21 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 Rinvoq for Psoriatic Arthritis (February 5, 2020)
26 Taltz for Psoriatic Arthritis (November 12, 2019)
27 Tremfya for Psoriatic Arthritis (November 11, 2019)
29 Cosentyx for Psoriatic Arthritis (November 1, 2019)
31 Rinvoq for Psoriatic Arthritis (October 31, 2019)
33 Inflectra for Psoriatic Arthritis (September 19, 2019)
34 Otezla for Psoriatic Arthritis (August 26, 2019)
35 Ilumya for Psoriatic Arthritis (June 27, 2019)
36 Ilumya for Psoriatic Arthritis (June 14, 2019)
38 Tremfya for Psoriatic Arthritis (June 14, 2019)
39 Cosentyx for Psoriatic Arthritis (June 12, 2019)
41 SensoReady Injector Pen for Psoriatic Arthritis (April 9, 2019)
43 KEY UPCOMING EVENTS
44 KEY REGULATORY EVENTS
44 Extra Indications Approved For Celltrion’s Remsima SC
44 FDA Approves Mylan’s Humira Biosimilar
44 J&J Bids To Strengthen Simponi’s Pediatric Labeling
44 Mylan And Lupin Get EU Etanercept Nod
45 Amgen To Launch Newly Approved Remicade Biosimilar Before July
45 Janssen Submits Tremfya For First-In-Class Active Psoriatic Arthritis Approval
46 PROBABILITY OF SUCCESS
47 LICENSING AND ASSET ACQUISITION DEALS
47 Bio-Thera Out-Licenses Golimumab To Russia And CIS
47 Deals Shaping The Medical Industry, January 2020
47 Amgen’s $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End
48 REVENUE OPPORTUNITY
52 CLINICAL TRIAL LANDSCAPE
53 Sponsors by status
54 Sponsors by phase
55 Recent events
57 BIBLIOGRAPHY
58 Prescription information
60 APPENDIX
LIST OF FIGURES
21 Figure 1: Overview of pipeline drugs for psoriatic arthritis in the US
21 Figure 2: Pipeline drugs for psoriatic arthritis, by company
22 Figure 3: Pipeline drugs for psoriatic arthritis, by drug type
22 Figure 4: Pipeline drugs for psoriatic arthritis, by classification
26 Figure 5: Rinvoq for Psoriatic Arthritis (February 5, 2020): Phase III – SELECT-PsA-1
29 Figure 6: Tremfya for Psoriatic Arthritis (November 11, 2019): Phase III – Discover-1, Phase III – Discover-2
31 Figure 7: Cosentyx for Psoriatic Arthritis (November 1, 2019): Phase IIIb – EXCEED 1 (vs. Adalimumab)
33 Figure 8: Rinvoq for Psoriatic Arthritis (October 31, 2019): Phase III – SELECT-PsA-2
38 Figure 9: Ilumya for Psoriatic Arthritis (June 14, 2019): Phase IIb – CLR_16_23
39 Figure 10: Tremfya for Psoriatic Arthritis (June 14, 2019): Phase III – Discover-1, Phase III – Discover-2
41 Figure 11: Cosentyx for Psoriatic Arthritis (June 12, 2019): Phase IIIb – MAXIMISE
43 Figure 12: Key upcoming events in psoriatic arthritis
46 Figure 13: Probability of success in the psoriatic arthritis pipeline
52 Figure 14: Clinical trials in psoriatic arthritis
52 Figure 15: Top 10 drugs for clinical trials in psoriatic arthritis
53 Figure 16: Top 10 companies for clinical trials in psoriatic arthritis
53 Figure 17: Trial locations in psoriatic arthritis
54 Figure 18: Psoriatic arthritis trials status
55 Figure 19: Psoriatic arthritis trials sponsors, by phase
LIST OF TABLES
16 Table 1: Marketed drugs for psoriatic arthritis
23 Table 2: Pipeline drugs for psoriatic arthritis in the US
25 Table 3: Rinvoq for Psoriatic Arthritis (February 5, 2020)
27 Table 4: Taltz for Psoriatic Arthritis (November 12, 2019)
28 Table 5: Tremfya for Psoriatic Arthritis (November 11, 2019)
30 Table 6: Cosentyx for Psoriatic Arthritis (November 1, 2019)
31 Table 7: Rinvoq for Psoriatic Arthritis (October 31, 2019)
34 Table 8: Inflectra for Psoriatic Arthritis (September 19, 2019)
35 Table 9: Otezla for Psoriatic Arthritis (August 26, 2019)
36 Table 10: Ilumya for Psoriatic Arthritis (June 27, 2019)
37 Table 11: Ilumya for Psoriatic Arthritis (June 14, 2019)
38 Table 12: Tremfya for Psoriatic Arthritis (June 14, 2019)
40 Table 13: Cosentyx for Psoriatic Arthritis (June 12, 2019)
41 Table 14: SensoReady Injector Pen for Psoriatic Arthritis (April 9, 2019)
49 Table 15: Historical global sales, by drug ($m), 2015–19
51 Table 16: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Wound Care: Tissue-Engineered Skin Replacements and Active Wound Repair Mod... 
Sign up to the